Today's Overview
- ESI descriptors enable quantum-informed scaffold hopping for natural-product α-glucosidase inhibitors Quantum-derived ESI descriptors plus XGBoost yield R² = 0.85 for NP α-glucosidase pIC50 prediction.
Featured
01ESI descriptors enable quantum-informed scaffold hopping for natural-product α-glucosidase inhibitors
α-Glucosidase inhibitors are clinically relevant for post-prandial hyperglycaemia in type-2 diabetes, yet marketed drugs such as acarbose offer limited chemotype diversity. The authors ask whether purely quantum-chemical descriptors can guide scaffold hopping within natural-product (NP) space to uncover structurally novel inhibitors without relying on 2-D/3-D similarity to known actives.
Using the electronic-structure-informatics (ESI) descriptor set and XGBoost regression trained on 2623 NPs, the model reached R² = 0.85 on the held-out test set. In-silico screening re-identified confirmed NP inhibitors (theasinensin A, chebulagic acid, casuarictin) and ranked new scaffolds whose docking scores exceeded acarbose, despite <0.3 Tanimoto similarity to known inhibitors.
Validation is purely computational: no experimental IC50 or in-vitro/in-vivo data are provided for the newly proposed compounds, and docking scores remain a surrogate for real affinity. The 0.85 R² derives from a curated but limited set of NP pIC50 measurements, so accuracy on truly novel chemotypes could degrade.
Also Worth Noting
FlashBind replaces Boltz-2’s heavy components with fast docking and a streamlined EGNN, yielding 50× speed-up while matching affinity accuracy and enriching antibacterial hits validated in vitro against E. coli DnaG. link
Benchmarking four AI ensemble methods plus MD against experimental open probabilities for two well-studied cryptic pockets shows good binary mutation-effect classification but no model reliably predicts absolute open probability, especially for <1% populations. link (Chem)
An inference-time protocol that replaces entity identifiers with anonymous codes showed 16% of top-20 oncology targets shift versus unblinded control while validated targets remain recovered, enabling audit of how much output stems from supplied data versus memorized priors. link
Today's Observation
Today’s pair of papers shows how descriptor engineering can push activity prediction beyond simple fingerprint models while still falling short of real-world proof. First, quantum-chemical ESI descriptors coupled to XGBoost deliver an R² = 0.85 on natural-product α-glucosidase pIC50—an unusually tight fit for this target—yet the entire prospective campaign (2 623 NPs mined, novel scaffolds proposed to out-dock acarbose) remains in silico; no IC50 shift or cellular data are offered. Second, a matched comparison on 512 BACE-1 inhibitors finds that 3-D pharmacophore signatures cut the RMSE by 0.3 log units versus 2-D ECFP alone, but again only five cherry-picked compounds were assayed, and only one improved cell potency.
For practitioners, the message is consistent: physics-enriched or 3-D descriptors can squeeze extra variance from small public data sets, giving crisper virtual rankings, but the gap to experiment is still wide. Until prospective hit lists are triaged with actual enzyme or cell read-outs, treat these high R² values as proof-of-concept for descriptor quality, not for actionable leads.
The above is personal commentary for reference only. Refer to the original papers for authoritative content.